Elevated putamen D2 receptor binding potential in major depression with motor retardation: An [11C]raclopride positron emission tomography study

American Journal of Psychiatry

Volumn 163, Issue 9, 2006, Pages 1594-1602

  Meyer, Jeffrey H ^a   McNeely, Heather E ^b   Sagrati, Sandra ^b   Boovariwala, Anahita ^b   Martin, Krystle ^b   Verhoeff, N Paul L G ^b   Wilson, Alan A ^b   Houle, Sylvain ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ADULT; APPARATUS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINE BLOOD LEVEL; FEMALE; FINGER TAPPING TEST; HUMAN; IMAGE ANALYSIS; MAJOR DEPRESSION; MALE; MOTOR PERFORMANCE; MOTOR RETARDATION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR AFFINITY; TASK PERFORMANCE;

EID: 33749070832     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.9.1594     Document Type: Article

References (42)

1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340:249-258
2. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50:345-350
3. Colzi A, d'Agostini F, Kettler R, Borroni E, Da Prada M: Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm Suppl 1990; 32:79-84
4. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW: Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 1990; 55:981-988
5. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE: Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17:303-312
6. Kish SJ, Shannak K, Hornykiewicz O: Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988; 318:876-880
7. Raskin A, Friedman AS, DiMascio A: Cognitive and performance deficits in depression. Psychopharmacol Bull 1982; 18:196-202
8. Korf J, van Praag HM: Retarded depression and the dopamine metabolism. Psychopharmacologia 1971; 19:199-203
9. Post RM, Kotin J, Goodwin FK, Gordon EK: Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am J Psychiatry 1973; 130:67-72
10. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6:602-608
11. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ: Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6:279-287
12. Lammertsma AA, Hume SP: Simplified Reference Tissue Model for PET Receptor Studies. 1996; 4:153-158
13. Laruelle M: Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20:423-451
14. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C, Papatheodorou G, Zipursky RB: A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001; 25:213-223
15. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS: Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192
16. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U: Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990; 5:55-59
17. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS: Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism: diagnostic implications of the D2 receptor status. Brain 1993; 116(pt 4):853-867
18. D'Haenen HA, Bossuyt A: Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994; 35:128-132
19. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W: Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 1999; 90:91-101
20. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP: Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997; 27:1247-1256
21. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van Heertum R, Mann JJ, Laruelle M: Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001; 50:313-322
22. Ebert D, Feistel H, Loew T, Pirner A: Dopamine and depression: striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) 1996; 126:91-94
23. Smith GS, Dewey SL, Brodie JD, Logan J, Vitkun SA, Simkowitz P, Schloesser R, Alexoff DA, Hurley A, Cooper T, Volkow ND: Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry 1997; 154:490-496
24. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J: Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998; 155:344-349
25. Spreen O, Strauss E: A Compendium of Neuropsychological Tests. New York, Oxford University Press, 1998
26. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, Lee GS, Huang J, Hahn EL, Mandelkern MA: Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004; 161:1211-1218
27. Biais MA, Norman DK: A psychometric evaluation of the DSM-IV personality disorder criteria. J Personal Disord 1997; 11:168-176
28. Burger C, Buck A: Requirements and implementation of a flexible kinetic modelling tool. J Nucl Med 1997; 38:1818-1823
29. Studholme C, Hill D, Hawkes D: An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognition 1999; 32:71-86
30. Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520
31. Ashburner J, Friston KJ: Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999; 7:254-266
32. Meyer JH, Gunn RN, Myers R, Grasby PM: Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999; 9:545-553
33. Pal P, Lee C, Samii A, Schulzer M, Stoessl A, Mak E, Wudel J, Dobko T, Tsui J: Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki. Parkinsonism Relat Dis 2001; 7:305-309
34. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH: Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001; 12:4121-4125
35. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding VS, Kennedy J, Wilson AA: Brain serotonin transporter binding potential measured with [11C]DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004; 61:1271-1279
36. Kilbourn MR, Sherman PS, Pisani T: Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 1992; 216:109-112
37. Gordon I, Weizman R, Rehavi M: Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996; 298:27-30
38. Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, Pirker W, Konstantinidis A, Kasper S: Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 2001; 31:1467-1473
39. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002; 163:102-105
40. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003; 28:413-420
41. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B: In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003; 54:800-805
42. Butcher SP, Liptrot J, Aburthnott GW: Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci Lett 1991; 122:245-248